(redirected from Tasmar)


an agent used as an adjunct to levodopa and carbidopa in treatment of Parkinson's disease.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Catecholamine inhibitor

Therapeutic class: Antiparkinsonian

Pregnancy risk category C

FDA Box Warning

Before prescribing or administering drug, make sure you're thoroughly familiar with prescribing information.

Don't administer until prescriber has discussed risks with patient and patient has provided written acknowledgment that risks have been explained.

Due to risk of hepatocellular injury (including potentially fatal, acute fulminant liver failure), drug ordinarily should be used in patients with Parkinson's disease who are receiving L-dopa/carbidopa, experiencing symptom fluctuations, and not responding satisfactorily to or not appropriate candidates for other adjunctive therapies. Withdraw therapy if patient doesn't show substantial benefit within 3 weeks of starting drug.

Don't initiate therapy if patient has clinical evidence of hepatic disease. Don't restart therapy if patient developed hepatocellular injury while receiving drug and was withdrawn from therapy for any reason.

Before and during therapy, obtain appropriate tests to exclude liver disease. Discontinue drug if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceed two times the upper limit of normal or if clinical signs and symptoms suggest onset of hepatic dysfunction.


Unknown. When given with levodopacarbidopa, thought to reversibly inhibit catechol O-methyltransferase, leading to increased levodopa bioavailability and stimulation in brain.


Tablets: 100 mg, 200 mg

Indications and dosages

Adjunct to levodopa-carbidopa in idiopathic Parkinson's disease

Adults: Initially, 100 mg P.O. t.i.d. given with levodopa-carbidopa. If beneficial, may increase dosage to 200 mg P.O. t.i.d.; maximum dosage is 600 mg daily. If response inadequate after 3 weeks, stop therapy.


• Hypersensitivity to drug

• Nontraumatic rhabdomyolysis

• Drug-related hyperpyrexia or confusion

• Hepatic disease, alanine aminotransferase or aspartate aminotransferase elevation

• History of tolcapone-induced hepatocellular injury


Use cautiously in:

• renal or cardiac disease, hypertension, asthma

• concurrent use of nonselective MAO inhibitor (such as phenelzine, tranylcypromine)

• pregnant or breastfeeding patients.


Before giving first dose, obtain patient's written informed consent for drug therapy.

• Check liver function tests before starting drug.

Don't stop drug abruptly, because this may cause a syndrome similar to neuroleptic malignant syndrome.

• Know that levodopa-carbidopa dosage may be decreased to minimize dyskinesia.

Adverse reactions

CNS: dizziness, asthenia, headache, fatigue, hypokinesia, mental deficiency, agitation, tremor, hyperactivity, paresthesia, irritability, syncope, depression, speech disorder, confusion, sleep disorder, excessive dreaming, hallucinations, drowsiness, hypertonia, imbalance, falling, hyperkinesias, dystonia, dyskinesia

CV: hypotension, chest discomfort or pain, orthostatic hypotension, palpitations

EENT: tinnitus, sinus congestion, pharyngitis

GI: nausea, vomiting, diarrhea, constipation, dyspepsia, abdominal pain, flatulence, dry mouth, anorexia

GU: hematuria, urinary tract infection (UTI), urinary incontinence, urine discoloration, urinary disorder, erectile dysfunction

Hepatic: jaundice, severe hepatocellular injury (including fulminant hepatic failure, death)

Musculoskeletal: neck pain, arthritis, muscle cramps, stiffness, rhabdomyolysis

Respiratory: upper respiratory infection, dyspnea, bronchitis

Skin: rash, dermal bleeding, diaphoresis

Other: fever, influenza


Drug-drug. Desipramine: increased risk of adverse tolcapone reactions

Nonselective MAO inhibitors (such as phenelzine, tranylcypromine): inhibition of principal pathways of tolcapone metabolism

Warfarin: increased warfarin blood level

Drug-diagnostic tests. Alanine aminotransferase, aspartate aminotransferase: increased levels

Patient monitoring

• Monitor parkinsonian symptoms during first 3 weeks of therapy. Report improvement (or lack thereof) to help determine if therapy should continue.

• Assess neurologic status closely.

Monitor liver function tests. Watch closely for signs and symptoms of hepatic impairment.

• Closely monitor temperature. Stay alert for fever and other indications of infection (particularly upper respiratory infection, influenza, and UTI).

Patient teaching

• Tell patient to take drug with first levodopa-carbidopa dose of day.

2Advise patient to immediately report signs or symptoms of liver problems (persistent nausea, fatigue, appetite loss, dark urine, itching, tenderness on right side of abdomen, and yellowing of skin or eyes).

• Instruct patient to promptly report signs and symptoms of infection.

Advise female patient to immediately report suspected pregnancy. Caution her not to breastfeed.

• Tell patient drug may cause involuntary movements, hallucinations, light-headedness, and other significant reactions. Urge him to use safety measures as needed.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• Advise patient to move slowly when sitting up or standing, to avoid dizziness from sudden blood pressure decrease.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


Tasmar® Neurology A COMT inhibitor used with levodopa/carbidopa to treat Parkinson's disease Adverse effects Liver toxicity
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Two COMT inhibitors marketed in the United States are entacapone (Comtan [R]) and tolcapone (Tasmar [R]).
The drug was approved as Tasmar in January 1998 for adjunctive use in patients whose Parkinson's symptoms are not adequately controlled despite being on adequate doses of levodopa/carbidopa, according to the FDA.
The FDA also has recommended that informed consent forms be a prerequisite to the prescription of Accutane and Thalomid, both of which are associated with severe birth defects, as well as Rezulin, which is prescribed for the treatment of diabetes, Tasmar, which is prescribed for the treatment of Parkinson's disease, and Felbatol, which is used in the treatment of epilepsy.
Tasmar also has a 24 hour distress capability via auto seaphone on channels 80, 81 and 82.
Anti-Parkinsonian drugs such as Artane, Tasmar, and Requip have side effects ranging from moderate to severe, many of which become less pronounced with continued use, reduction in dosage, or minimization of drug interactions.
Pharmaceutical giant Roche confirmed last night that the drug, Tasmar, has been taken off the market in Britain and the rest of the EU "until further notice" at the request of the European Commission.
In the first 6 months of 1997, the following new drugs were approved by the FDA: Agrylin, Alesse, Anzemet, Carbatrol, Fareston, Flomax, Galzin, Idamycin, Migranal, Posicor, Prelay, Prevacid, Pytest, Requip, Resulin, Serlect, Skelid, Tasmar, Uniretic, Urso, Vicoprofen, Viracept, Zyban.
entacapone 200 mg with $8.40 (five (Comtan) each dose of times a day) levodopa tolcapone 100-200 $7.29 (Tasmar) mg t.i.d (100 mg t.i.d) MONOAMINE OXIDASE TYPE B INHIBITOR selegiline 5 mg once or $3.88 twice daily (5 mg b.i.d.) Drug Comment ** DOPAMINE PRECURSOR carbidopa/levodopa Decreases the amount of levodopa needed and lessens some side effects.
tolcapone 100-200 $7.29 Inhibits COMT for longer periods (Tasmar) mg t.i.d t.i.d) than entacapone, but not as effective for reducing levodopa dose.
Tolcapone (Tasmar) is the first COMT inhibitor to be available and works both peripherally and centrally to allow a greater half-life of levodopa and dopamine.[25] While promising for the treatment of PD, tolcapone has recently been shown to potentially cause fulminant idiosyncratic hepatic failure, resulting in three known deaths.
Tolcapone (Tasmar) was removed from the European market due to hepatotoxicity.
One of the drugs, tolcapone (Tasmar), has been relabeled following deaths in 3 patients from acute, severe liver failure.